A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis compared with Factor VIII (FVIII) prophylaxis in participants with severe or moderate congenital hemophilia A without inhibitors. The study will include people aged ≥12 years old with severe or moderate congenital hemophilia A without inhibitors on previous FVIII prophylaxis treatment.

NCT Number	NCT07416526
Lead Sponsor	Hoffmann-La Roche Collaborators: Chugai Pharmaceutical
Conditions	Hemophilia A
Enrollment	126 participants
Start Date	2026-05-15
Primary Completion	2027-09-23 (estimated)
Study Completion	2031-09-23 (estimated)
Updated on ClinicalTrials.gov	2026-08-06